Latest news and press releases about Aldeyra The (ALDX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
Price
| Price | $1.37 |
| Market Cap | $83M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.18 |
| EV / EBITDA | -2.07 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -53.14% |
| Return on Invested Capital | -63.28% |
| Return on Assets | -48.49% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACIU · AMRN · ANRO · CADL · CLLS · CTNM · GNLX
Explore sector: Healthcare · Biotechnology
More sections of ALDX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks